Show simple item record

dc.contributor.authorPetrushkin, Hen_US
dc.contributor.authorRogers, Den_US
dc.contributor.authorPavesio, Cen_US
dc.date.accessioned2017-02-20T10:03:13Z
dc.date.available2016-12-05en_US
dc.date.issued2018en_US
dc.date.submitted2017-02-14T17:15:36.162Z
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/19440
dc.description.abstractThe use of topical non-steroidal anti-inflammatory drugs in the management of uveitic cystoid macular edema is controversial. In this letter, we review the literature and report our results from a retrospective case series of 281 patients taking topical nepafenac 0.1% for uveitic cystoid macular edema between 2010 and 2016. Over a 4-month period, there was a modest improvement in best-corrected visual acuity (0.66 ± 3.7 logMAR) and central macular thickness (69.8 ± 132.5 μm). Patients with idiopathic anterior uveitis and HLA-B*27-associated anterior uveitis recovered more vision while taking topical nepafenac 0.1%, than those with other uveitides, however, this was not statistically significant. There is a need for controlled prospective studies to evaluate the efficacy of topical non-steroidal anti-inflammatory drugs in the management of uveitic cystoid macular edema. At present, clinicians have little evidence on which to base practice.en_US
dc.format.extent795 - 797en_US
dc.languageengen_US
dc.relation.ispartofOcul Immunol Inflammen_US
dc.rightsThis is an Accepted Manuscript of an article published by Taylor & Francis in Ocular Immunology and Inflammation on 12 Jan 2017, available online: http://www.tandfonline.com/10.1080/09273948.2016.1269931.
dc.subjectCystoid macular edemaen_US
dc.subjectNSAIDsen_US
dc.subjectnepafenacen_US
dc.subjectnevanacen_US
dc.subjectnon-steroidal anti-inflammatory drugsen_US
dc.subjectuveiticen_US
dc.subjectuveitisen_US
dc.subjectAdministration, Topicalen_US
dc.subjectAnti-Inflammatory Agents, Non-Steroidalen_US
dc.subjectBenzeneacetamidesen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectMacula Luteaen_US
dc.subjectMacular Edemaen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectPhenylacetatesen_US
dc.subjectTomography, Optical Coherenceen_US
dc.subjectUveitisen_US
dc.subjectVisual Acuityen_US
dc.titleThe Use of Topical Non-steroidal Anti-inflammatory Drugs for Uveitic Cystoid Macular Edema.en_US
dc.typeArticle
dc.rights.holder© 2017 Informa UK Limited.
dc.identifier.doi10.1080/09273948.2016.1269931en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/28080174en_US
pubs.issue5en_US
pubs.notesNot knownen_US
pubs.organisational-group/Queen Mary University of London
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Institute of Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Institute of Dentistry/Clinical & Diagnostic Oral Sciences
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Institute of Dentistry/Institute of Dentistry - Research Students
pubs.organisational-group/Queen Mary University of London/Faculty Reporting - Research Students
pubs.organisational-group/Queen Mary University of London/Faculty Reporting - Research Students/Faculty of Medicine & Dentistry PGRs
pubs.publication-statusPublisheden_US
pubs.volume26en_US
qmul.funderThe Genetic Basis of KIR3DL1 - HLA-B*51 interactions in Behcet's Disease::The Royal College of Ophthalmology / Pfizer Fellowshipen_US
qmul.funderThe Genetic Basis of KIR3DL1 - HLA-B*51 interactions in Behcet's Disease::The Royal College of Ophthalmology / Pfizer Fellowshipen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record